DPYD: A Potential Drug Target and Biomarker (G1806)

Target Name: DPYD

NCBI ID: G1806

DPYD

DPYD: A Potential Drug Target and Biomarker

DPYD (Dopamine-Pyruvate Dehydrogenase) is a protein that is expressed in various tissues and cells in the central nervous system (CNS). It is a key enzyme in the metabolism of dopamine, which is a neurotransmitter that plays a crucial role in the regulation of mood, motivation, and reward. The dysfunction of DPYD has been implicated in a number of neurological disorders, including Parkinson's disease, addiction, and schizophrenia. As a result, DPYD has emerged as a promising drug target and biomarker for the development of new treatments for these disorders.

DPYD is an enzyme that catalyzes the metabolism of dopamine by converting it to pyruvate, which is then converted to glucose and carbon dioxide. This metabolism is critical for the normal functioning of dopamine, as it allows it to be broken down and eliminated from the brain. However, when DPYD is impaired or dysfunctional, it can lead to an accumulation of dopamine and a build-up of toxic metabolites. This can cause a range of negative symptoms, including symptoms of Parkinson's disease, such as tremors, rigidity, and difficulty with movement.

DPYD has also been implicated in the development and progression of addiction, as well as in the treatment of addiction. Studies have shown that individuals with ADHD or other disorders that involve dysfunctional dopamine metabolism may be more likely to develop addiction, and that treatment with drugs that target DPYD may be effective in reducing the risk of relapse. Additionally,DPYD has been shown to be involved in the treatment of addiction, by increasing the levels of a protein called GABA, which has been shown to have anti-addictive properties.

DPYD also plays a role in the regulation of mood and reward. Imbalances in dopamine levels can contribute to symptoms of depression and anxiety, and DPYD has been shown to be involved in the regulation of these symptoms. Additionally, DPYD has been shown to be involved in the regulation of sexual desire and reward.

In conclusion, DPYD is a protein that is involved in the metabolism of dopamine and has been implicated in a number of neurological disorders, including Parkinson's disease, addiction, and schizophrenia. As a result, it has emerged as a promising drug target and biomarker for the development of new treatments for these disorders. Further research is needed to fully understand the role of DPYD in the treatment of these disorders and to develop safe and effective drugs that target it.

Protein Name: Dihydropyrimidine Dehydrogenase

Functions: Involved in pyrimidine base degradation (PubMed:1512248). Catalyzes the reduction of uracil and thymine (PubMed:1512248). Also involved the degradation of the chemotherapeutic drug 5-fluorouracil (PubMed:1512248)

The "DPYD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DPYD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets